Email Updates

Search form

You are here

TAF as Effective as TDF in Cisgender Women, with Fewer Side Effects

Include in
Media Coverage

Initial data gathered from seven separate studies found tenofovir alafenamide (TAF) is just as effective as tenofovir disoproxil fumarate (Viread, TDF), with fewer side effects to the kidneys and bones, when used in cisgender women. These results, presented this week at the Conference on Retroviruses and Opportunistic Infections (CROI 2019) in Seattle, are similar to those found in cisgender men.

March 8, 2019
The BodyPro